MedTrace Logo

The Comparison of Sympathetic Blockade of Stellate Ganglion Block and Thoracic Paravertebral Block

NCT04876989 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2023-10-17

No results posted yet for this study

Summary

The purpose of this study is to investigate the effect of ultrasound-guided thoracic paravertebral block (TPVB) when performing sympathetic block for upper limb pain control.

Conditions

  • Complex Regional Pain Syndromes
  • Postherpetic Neuralgia
  • Phantom Limb Pain
  • Chronic Post Surgical Pain
  • Post-Traumatic Neuralgia
  • Neuropathic Pain

Interventions

PROCEDURE

US-SGB

Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 5 ml of 1% mepivacaine is injected for the US-SGB group.

PROCEDURE

US-TPVB

Well trained pain physician performs all the ultrasound(US)-guided thoracic paravertebral block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided TPVB, patients are prone positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at T2 paravertebral space. 10 ml of 1% mepivacaine is injected for the US-TPVB group.

Sponsors & Collaborators

  • SMG-SNU Boramae Medical Center

    collaborator OTHER

  • Seoul National University

    lead OTHER

Principal Investigators

  • Youn Moon Jee, MD, PhD · Seoul National University Hospital

  • Jeongsoo Kim, MD · SMG-SNU Boramae Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-21
Primary Completion
2022-12-19
Completion
2023-01-16

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04876989 on ClinicalTrials.gov